Cargando…
Long-lasting severe immune dysfunction in Ebola virus disease survivors
Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18–25]) after discharge from treatment center. Compared with healthy...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381622/ https://www.ncbi.nlm.nih.gov/pubmed/32709840 http://dx.doi.org/10.1038/s41467-020-17489-7 |
_version_ | 1783563082101948416 |
---|---|
author | Wiedemann, Aurélie Foucat, Emile Hocini, Hakim Lefebvre, Cécile Hejblum, Boris P. Durand, Mélany Krüger, Miriam Keita, Alpha Kabinet Ayouba, Ahidjo Mély, Stéphane Fernandez, José-Carlos Touré, Abdoulaye Fourati, Slim Lévy-Marchal, Claire Raoul, Hervé Delaporte, Eric Koivogui, Lamine Thiébaut, Rodolphe Lacabaratz, Christine Lévy, Yves |
author_facet | Wiedemann, Aurélie Foucat, Emile Hocini, Hakim Lefebvre, Cécile Hejblum, Boris P. Durand, Mélany Krüger, Miriam Keita, Alpha Kabinet Ayouba, Ahidjo Mély, Stéphane Fernandez, José-Carlos Touré, Abdoulaye Fourati, Slim Lévy-Marchal, Claire Raoul, Hervé Delaporte, Eric Koivogui, Lamine Thiébaut, Rodolphe Lacabaratz, Christine Lévy, Yves |
author_sort | Wiedemann, Aurélie |
collection | PubMed |
description | Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18–25]) after discharge from treatment center. Compared with healthy donors, EBOV_S exhibit increases of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and a depletion of circulating dendritic cells. All survivors have EBOV-specific IgG antibodies and robust and polyfunctional EBOV-specific memory T-cell responses. Deep sequencing of the genes expressed in blood reveals an enrichment in ‘inflammation’ and ‘antiviral’ pathways. Integrated analyses identify specific immune markers associated with the persistence of clinical symptoms. This study identifies a set of biological and genetic markers that could be used to define a signature of “chronic Ebola virus disease (CEVD)”. |
format | Online Article Text |
id | pubmed-7381622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73816222020-07-28 Long-lasting severe immune dysfunction in Ebola virus disease survivors Wiedemann, Aurélie Foucat, Emile Hocini, Hakim Lefebvre, Cécile Hejblum, Boris P. Durand, Mélany Krüger, Miriam Keita, Alpha Kabinet Ayouba, Ahidjo Mély, Stéphane Fernandez, José-Carlos Touré, Abdoulaye Fourati, Slim Lévy-Marchal, Claire Raoul, Hervé Delaporte, Eric Koivogui, Lamine Thiébaut, Rodolphe Lacabaratz, Christine Lévy, Yves Nat Commun Article Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18–25]) after discharge from treatment center. Compared with healthy donors, EBOV_S exhibit increases of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and a depletion of circulating dendritic cells. All survivors have EBOV-specific IgG antibodies and robust and polyfunctional EBOV-specific memory T-cell responses. Deep sequencing of the genes expressed in blood reveals an enrichment in ‘inflammation’ and ‘antiviral’ pathways. Integrated analyses identify specific immune markers associated with the persistence of clinical symptoms. This study identifies a set of biological and genetic markers that could be used to define a signature of “chronic Ebola virus disease (CEVD)”. Nature Publishing Group UK 2020-07-24 /pmc/articles/PMC7381622/ /pubmed/32709840 http://dx.doi.org/10.1038/s41467-020-17489-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Wiedemann, Aurélie Foucat, Emile Hocini, Hakim Lefebvre, Cécile Hejblum, Boris P. Durand, Mélany Krüger, Miriam Keita, Alpha Kabinet Ayouba, Ahidjo Mély, Stéphane Fernandez, José-Carlos Touré, Abdoulaye Fourati, Slim Lévy-Marchal, Claire Raoul, Hervé Delaporte, Eric Koivogui, Lamine Thiébaut, Rodolphe Lacabaratz, Christine Lévy, Yves Long-lasting severe immune dysfunction in Ebola virus disease survivors |
title | Long-lasting severe immune dysfunction in Ebola virus disease survivors |
title_full | Long-lasting severe immune dysfunction in Ebola virus disease survivors |
title_fullStr | Long-lasting severe immune dysfunction in Ebola virus disease survivors |
title_full_unstemmed | Long-lasting severe immune dysfunction in Ebola virus disease survivors |
title_short | Long-lasting severe immune dysfunction in Ebola virus disease survivors |
title_sort | long-lasting severe immune dysfunction in ebola virus disease survivors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381622/ https://www.ncbi.nlm.nih.gov/pubmed/32709840 http://dx.doi.org/10.1038/s41467-020-17489-7 |
work_keys_str_mv | AT wiedemannaurelie longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT foucatemile longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT hocinihakim longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT lefebvrececile longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT hejblumborisp longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT durandmelany longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT krugermiriam longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT keitaalphakabinet longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT ayoubaahidjo longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT melystephane longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT fernandezjosecarlos longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT toureabdoulaye longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT fouratislim longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT levymarchalclaire longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT raoulherve longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT delaporteeric longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT koivoguilamine longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT thiebautrodolphe longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT lacabaratzchristine longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT levyyves longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors AT longlastingsevereimmunedysfunctioninebolavirusdiseasesurvivors |